Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.70 USD
Change Today -0.0248 / -3.43%
Volume 9.2K
NEPH On Other Exchanges
Symbol
Exchange
OTC BB
As of 10:13 AM 04/27/15 All times are local (Market data is delayed by at least 15 minutes).

nephros inc (NEPH) Snapshot

Open
$0.75
Previous Close
$0.72
Day High
$0.75
Day Low
$0.70
52 Week High
06/2/14 - $1.29
52 Week Low
04/28/14 - $0.42
Market Cap
21.3M
Average Volume 10 Days
13.8K
EPS TTM
$-0.16
Shares Outstanding
30.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NEPHROS INC (NEPH)

Related News

No related news articles were found.

nephros inc (NEPH) Related Businessweek News

No Related Businessweek News Found

nephros inc (NEPH) Details

Nephros, Inc., a commercial stage medical device company, develops and sells high performance liquid purification filters primarily in the United States. It offers ultrafilters for hospitals and other commercial facilities that filter water for patient washing and drinking, as well as wound cleansing, medical equipment cleaning, and surgeons’ hands washing. The company also provides ultrafilters for dialysis centers that filters water or bicarbonate concentrate for use in hemodialysis devices, as well as clearance of toxins from blood in the treatment of patients with chronic renal failure; for individual water purification devices to produce drinking water for soldiers and backpackers in the military and outdoor recreation field; and for commercial facilities that filter water for use in ice machines and soda fountains. In addition, it offers products in the hemodiafiltration (HDF) modality to deliver therapy for end stage renal disease patients, which include OLpur mid-dilution HDF filter for HDF therapy; and OLpur H2H HDF module, an add-on module designed to allow the common types of hemodialysis machines for use in HDF therapy. The company was founded in 1997 and is headquartered in River Edge, New Jersey.

7 Employees
Last Reported Date: 04/15/15
Founded in 1997

nephros inc (NEPH) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

nephros inc (NEPH) Key Developments

Nephros, Inc. Announces Financial Results for the Full Year Ended December 31, 2014; Provides Earnings Guidance for 2015

Nephros, Inc. announced financial results for the full year ended December 31, 2014. For the full year, the company reported total revenues for the year ended December 31, 2014 were approximately $1,748,000 compared to approximately $1,740,000 for the year ended December 31, 2013. An increase of approximately $123,000 related to the Bellco license agreement was offset by a decrease in water filter sales of $115,000. For full-year 2015, The company anticipates significantly increased product revenue vs. full-year 2014, driven primarily by increased sales of hospital infection control filters. The company intends to focus efforts on expanding the market penetration of water filtration products by enhancing relationships with key distributors. The company continues to pursue opportunities for expansion of dialysis water filter sales, but growth of this product line is anticipated to be incremental in 2015 vs. 2014.

Nephros, Inc. Announces Management Changes

Nephros, Inc. announced that Daron Evans has been appointed President and Chief Executive Officer. Effective upon Mr. Evans’s appointment, Dr. Paul Mieyal stepped down as acting CEO of Nephros and will remain as a member of the company’s board of directors. Additionally, Lawrence Centella has been appointed Chairman of the Board of Directors. Mr. Evans has served on Nephros’ board of directors since 2013. He is a life sciences executive with over 20 years of financial leadership and operational experience. Mr. Evans was recently Managing Director of PoC Capital, LLC, and is a member of the board of Zumbro Discovery, Inc. From 2007 to 2013, Mr. Evans was Chief Financial Officer of Nile Therapeutics, Inc. Mr. Centella has served as a director of Nephros since January 2001. Mr. Centella served as President of Renal Patient Services, LLC and served in such capacity from June 1998 to 2014. Mr. Centella is also the founder of LADA International, Inc.

Nephros, Inc. Auditor Raises 'Going Concern' Doubt

Nephros, Inc. filed its 10-K on Apr 15, 2015 for the period ending Dec 31, 2014. In this report its auditor, WithumSmith+Brown, PC , gave an unqualified opinion expressing doubt that the company can continue as a going concern.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NEPH:US $0.70 USD -0.0248

NEPH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Baxter International Inc $70.66 USD -0.48
Fresenius Medical Care AG & Co KGaA €80.20 EUR +0.60
Nikkiso Co Ltd ¥1,122 JPY +3.00
View Industry Companies
 

Industry Analysis

NEPH

Industry Average

Valuation NEPH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 10.8x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 11.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEPHROS INC, please visit www.nephros.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.